Coeptis Therapeutics, Inc. (COEP)

NASDAQ: COEP · IEX Real-Time Price · USD
+0.08 (5.33%)
Jan 27, 2023, 4:00 PM EST - Market closed

Company Description

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer.

Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies.

The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease.

Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Coeptis Therapeutics, Inc.
Coeptis Therapeutics logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Mr. David Mehalick

Contact Details

105 Bradford Rd, Suite 420
Wexford, Pennsylvania 15090
United States
Phone 724-934-6467

Stock Details

Ticker Symbol COEP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001819663
CUSIP Number 19207C104
ISIN Number US19207C1045
Employer ID 84-3998117
SIC Code 2834

Key Executives

Name Position
David Mehalick Co-Founder, Chairman, Chief Executive Officer and Pres
Christine Elise Sheehy Co-Founder, Chief Financial Officer and Secretary
Daniel Alexander Yerace Co-Founder, Vice President of Operations and Director
Gary R. Conte Senior Vice President of Sales and Marketing

Latest SEC Filings

Date Type Title
Dec 14, 2022 15-12G Securities registration termination
Nov 8, 2022 10-Q Quarterly Report
Oct 28, 2022 8-K Current Report
Sep 30, 2022 DEFM14A Filing
Sep 21, 2022 8-K Current Report
Sep 21, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 19, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2022 PREM14A Filing
Sep 7, 2022 253G2 Acc-no: 0001493152-21-027927 (33 Act)
Sep 7, 2022 8-K Current Report